Presentation Title: | Safety, Pharmacokinetics, and Pharmacodynamics Results From a Phase 1 Trial of BAY 86-9766 (RDEA119), a MEK Inhibitor, In Patients with Advanced Cancer | |
Session Type/Title: | Oral Abstract Session: Developmental Therapeutics – Experimental Therapeutics | |
Author/Presenter: | Colin Weekes, MD, PhD – Assistant Professor, Division of Medical Oncology, University of Colorado School of Medicine | |
Abstract ID: | 3007 | |
Date/Time: | Sunday, June 5, 2011 from 9:30 AM – 12:30 PM CDT | |
